Carregant...
Trial Watch: Adoptive cell transfer for oncological indications
One particular paradigm of anticancer immunotherapy relies on the administration of (potentially) tumor-reactive immune effector cells. Generally, these cells are obtained from autologous peripheral blood lymphocytes (PBLs) ex vivo (in the context of appropriate expansion, activation and targeting p...
Guardat en:
| Publicat a: | Oncoimmunology |
|---|---|
| Autors principals: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4590013/ https://ncbi.nlm.nih.gov/pubmed/26451319 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1046673 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|